Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ therapeutic use
Carcinoma, Renal Cell
/ drug therapy
Everolimus
/ therapeutic use
Female
Germany
Humans
Kaplan-Meier Estimate
Kidney Neoplasms
/ drug therapy
Male
Middle Aged
Molecular Targeted Therapy
/ methods
Retrospective Studies
Sunitinib
/ therapeutic use
Sweden
TOR Serine-Threonine Kinases
/ antagonists & inhibitors
Journal
Acta oncologica (Stockholm, Sweden)
ISSN: 1651-226X
Titre abrégé: Acta Oncol
Pays: England
ID NLM: 8709065
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
pubmed:
7
12
2018
medline:
12
7
2019
entrez:
4
12
2018
Statut:
ppublish
Résumé
Metastatic papillary renal cell carcinoma (mPRCC) is understudied. The disease is often aggressive and specific treatment options are lacking. mPRCC patients (n = 86) referred to three academic centres in Sweden and Germany in the years 2005-2015 were retrospectively identified from medical records. Statistical analyses included Kaplan-Meier curves and calculation of Cox proportional hazards, generating hazard ratios with 95% confidence intervals. The aim of the study was to evaluate overall survival (OS) of mPRCC patients treated outside of clinical trials in the era of targeted agents (TA) and to identify clinically useful prognostic factors. Median OS of all mPRCC patients was 11.2 months. TA were used in 77% of the patients and associated with younger age and better Eastern Cooperative Oncology Group performance status (PS). Brain metastases were common (28%). Patients with synchronous or metachronous metastases had similar OS. Variables independently associated with risk of death included age ≥60 years, worse PS and ≥3 metastatic sites. The MSKCC criteria did not provide additional prognostic information. A subgroup analysis of TA-treated patients revealed an association of lymph node metastasis with risk of death in addition to the other prognostic factors. OS in mPRCC remained short in the era of targeted agents. Age, PS, and number of metastatic sites provided independent prognostic information.
Sections du résumé
BACKGROUND
BACKGROUND
Metastatic papillary renal cell carcinoma (mPRCC) is understudied. The disease is often aggressive and specific treatment options are lacking.
PATIENTS AND METHODS
METHODS
mPRCC patients (n = 86) referred to three academic centres in Sweden and Germany in the years 2005-2015 were retrospectively identified from medical records. Statistical analyses included Kaplan-Meier curves and calculation of Cox proportional hazards, generating hazard ratios with 95% confidence intervals. The aim of the study was to evaluate overall survival (OS) of mPRCC patients treated outside of clinical trials in the era of targeted agents (TA) and to identify clinically useful prognostic factors.
RESULTS
RESULTS
Median OS of all mPRCC patients was 11.2 months. TA were used in 77% of the patients and associated with younger age and better Eastern Cooperative Oncology Group performance status (PS). Brain metastases were common (28%). Patients with synchronous or metachronous metastases had similar OS. Variables independently associated with risk of death included age ≥60 years, worse PS and ≥3 metastatic sites. The MSKCC criteria did not provide additional prognostic information. A subgroup analysis of TA-treated patients revealed an association of lymph node metastasis with risk of death in addition to the other prognostic factors.
CONCLUSION
CONCLUSIONS
OS in mPRCC remained short in the era of targeted agents. Age, PS, and number of metastatic sites provided independent prognostic information.
Identifiants
pubmed: 30507262
doi: 10.1080/0284186X.2018.1537505
doi:
Substances chimiques
Antineoplastic Agents
0
Everolimus
9HW64Q8G6G
MTOR protein, human
EC 2.7.1.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Sunitinib
V99T50803M
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM